Assessment and Evolution of Narrative Identity and Its Relationship to Subjective Multidimensional Well-being and Multidimensional Recovery in First Episode Psychosis

NCT07330843 | Not Yet Recruiting

• 1 other identifier: LOCAL/2025/THESE/JJ-01
• Study Type: observational
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

First episode psychosis (FEP) constitutes an important subgroup within psychotic disorders, as the acute impact of a disorder at the time of diagnosis may differ from its long-term impact over the following decades. Narrative is identified as a sense of personal agency, of belonging to a social group, metacognition, and well-being. Patients with schizophrenia have lower levels of agency and communion compared to HIV-positive participants. However, the themes of agency and communion and metacognition do not reflect all factors representing narrative identity. In order to measure well-being, it is also necessary to introduce a specific and multidimensional measure that will allow a more precise understanding of the phenomenon. In FEP, a link has been demonstrated between the specificity of self-recollection and functional outcomes. Given that the transitional developmental stage between adolescence and adulthood is a key developmental window for narrative identity as well as psychotic disorders and that narrative identity is positively associated with mental health, this study will therefore focus on the acquisition of narrative identity in the FEP. It will investigate the extent to which narrative identity has an impact on multidimensional subjective well-being and whether it can predict multidimensional subjective well-being over time. The study investigators hypothesize that the levels of the various components of narrative identity would be lower in cases of FEP compared to patients with other "chronic" psychotic conditions and controls.

Conditions

Psychosis; Mental Disorder

Keywords

Narrative identity

Outcome Measures

Primary Outcomes (15)

• Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

  7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  Baseline (Day 0)

• Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

  7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  Month 6

• Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

  7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  Month 12

• Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

  7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  Month 18

• Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

  7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  Month 24

• Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

  7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  Baseline (Day 0)

• Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

  7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  Month 6

• Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

  7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  Month 12

• Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

  7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  Month 18

• Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

  7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  Month 24

• Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

  4-point scale ranging from 0 "Negative" to 4 "Positive."

  Baseline (day 0)

• Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

  4-point scale ranging from 0 "Negative" to 4 "Positive."

  Month 6

• Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

  4-point scale ranging from 0 "Negative" to 4 "Positive."

  Month 12

• Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

  4-point scale ranging from 0 "Negative" to 4 "Positive."

  Month 18

• Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

  4-point scale ranging from 0 "Negative" to 4 "Positive."

  Month 24

Secondary Outcomes (80)

• Narrative identity between groups

  Baseline (Day 0)

• Narrative identity between groups

  Month 6

• Narrative identity between groups

  Month 12

• Narrative identity between groups

  Month 18

• Narrative identity between groups

  Month 24

Study Arms (3)

First episode psychosis

Other: Narrative identity task

Chronic

participants diagnosed with a psychotic disorder

Other: Narrative identity task

Control

Other: Narrative identity task

Interventions

Narrative identity task OTHER

Participants will be asked to elaborate five personal narratives in response to the different types of questions: trauma, transgression, negative memory, self-definition, and turning point.

Chronic; Control; First episode psychosis

Eligibility Criteria

• Age: 16 Years - 30 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

406 / 5,000 Three groups of participants will be formed: 1. a group of participants meeting the criteria for a FEP; 2. a group of "chronic" participants diagnosed with a psychotic disorder (recruited from patients at the Carémeau University Hospital in Nîmes); and 3. a control group of participants, representative of the general population (recruited through social media advertisements).

You may qualify if:

• Subject who has given their free and informed consent.
• Subject who has signed the consent form.
• Subject who is a member of or beneficiary of a health insurance plan.
• For the FEP group:
• Patient treated in a psychiatric department (consultation or hospitalization) for a FEP defined by:
• Presence of positive psychotic symptoms (delusions and/or hallucinations and/or conceptual disorganization) evolving for at least one week, either every day or at least 3 times a week for at least one hour per occasion
• Never having taken neuroleptic treatment with an antipsychotic purpose (with the exception of antipsychotic treatment initiated for the current episode)
• Disorder meeting DSM 5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar disorder I or II with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features
• For the "Chronic" group:
• Patients diagnosed with a disorder meeting DSM-5 criteria for more than 18 months from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features

You may not qualify if:

• The patient is unable to express consent
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship
• Pregnant or breastfeeding subject.
• Patient with a history of traumatic brain injury
• Patient with moderate to severe mental retardation (IQ ≤ 55)
• For the FEP group:
• FEP related to a drug-induced psychotic disorder or due to another medical condition
• For the "Control" group:
• Patient with lifetime experience of FEP
• Patient with a diagnosis of a disorder meeting DSM-5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophrenia-like disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, bipolar disorder with mood-congruent and mood-incongruent psychotic features substance-induced mood, major depressive disorder with psychotic features congruent and incongruent with mood

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, 30029, France

Location

MeSH Terms

Conditions

Psychotic Disorders; Mental Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders

Study Officials

• Julie Jourdan

  Centre Hospitalier Universitaire de Nīmes

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Julie Jourdan

CONTACT

04.66.68.34.26; julie.jourdan@chu-nimes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2025
• First Posted: January 9, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): July 1, 2029
• Study Completion (Estimated): July 1, 2029
• Last Updated: January 9, 2026

Record last verified: 2025-11

Locations

FR (1)